An updated view on the origin and use of angiogenic biomarkers for preeclampsia

References

• Townsend R, O’Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control. 2016;9:79–94.
   PubMed Web of Science ®Google Scholar
• Bellamy L, Casas JP, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: a systematic review and meta-analysis. Br Med J. 2007;335:974–977.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Task force on hypertension in pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–1131.
   PubMed Web of Science ®Google Scholar
• Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–339.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
   PubMed Web of Science ®Google Scholar
• Cureton N, Korotkova I, Baker B, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017;7(15):3715–3731.
   PubMed Web of Science ®Google Scholar
• Sharp A, Cornforth C, Jackson R, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018;2:93–102.
   PubMedGoogle Scholar
• Hawkes N. Trial of Viagra for fetal growth restriction is halted after baby deaths. Br Med J. 2018;362:k3247.
   PubMedGoogle Scholar
• Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51(4):970–975.
   PubMed Web of Science ®Google Scholar
• Huppertz B. The critical role of abnormal trophoblast development in the etiology of preeclampsia. Curr Pharm Biotechnol. 2018 Apr 26. [Epub ahead of print] PMID: 29701150. DOI:10.2174/1389201019666180427110547
   PubMedGoogle Scholar
• Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40–49.
   PubMed Web of Science ®Google Scholar
• Shear RM, Rinfret D, Leduc L. Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction? Am J Obstet Gynecol. 2005;192:1119–1125.
   PubMed Web of Science ®Google Scholar
• Weiler J, Tong S, Palmer KR. Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS One. 2011;6(10):e26937.
   PubMedGoogle Scholar
• Verlohren S, Melchiorre K, Khalil A, et al. Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia. Ultrasound Obstet Gynecol. 2014;44(3):293–298.
   PubMed Web of Science ®Google Scholar
• Perry H, Khalil A, Thilaganathan B. Preeclampsia and the cardiovascular system: an update. Trends Cardiovasc Med. 2018 May 15. pii: S1050-1738(18)30059-8. [Epub ahead of print]. DOI:10.1016/j.tcm.2018.04.009
   PubMed Web of Science ®Google Scholar
• Thilaganathan B. Pre-eclampsia and the cardiovascular-placental axis. Ultrasound Obstet Gynecol. 2018;51:714–717.
   PubMed Web of Science ®Google Scholar
• Wolff F, Frenkel H, Skoulios G, et al. The interest of the plasma estrone + estradiol/estriol relationship in the surveillance of threatened premature birth, late pre-eclampsia and prolonged pregnancy. Rev Fr Gynecol Obstet. 1973;68(2):93–97.
   PubMedGoogle Scholar
• Garoff L, Seppälä M. Alpha fetoprotein and human placental lactogen levels in maternal serum in multiple pregnancies. J Obstet Gynaecol Br Commonw. 1973;80(8):695–700.
   PubMedGoogle Scholar
• Rodeck CH, Campbell S, Biswas S. Maternal plasma alpha-fetoprotein in normal and complicated pregnancies. Br J Obstet Gynaecol. 1976;83(1):24–32.
   PubMedGoogle Scholar
• Walters BN, Lao T, Smith V, et al. Alpha-fetoprotein elevation and proteinuric pre-eclampsia. Br J Obstet Gynaecol. 1985;92(4):341–344.
   PubMedGoogle Scholar
• Krieger VI, Weiden S. The value of the cold pressor test in the prediction of hypertension and toxaemia in pregnancy. Med J Aust. 1947;1(14):417–423.
   PubMedGoogle Scholar
• Gillim DL. Evaluation of flicker fusion photometry its use in prediction of pre-eclampsia. Obstet Gynecol. 1954;4(3):264–269.
   PubMed Web of Science ®Google Scholar
• Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998;59(6):1540–1548.
   PubMed Web of Science ®Google Scholar
• Reuvekamp A, Velsing-Aarts FV, Poulina IE, et al. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1999;106(10):1019–1022.
   PubMedGoogle Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
   PubMed Web of Science ®Google Scholar
• Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant. 2006;21(11):3052–3054.
   PubMed Web of Science ®Google Scholar
• Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197(1):35.e1-7.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
   PubMed Web of Science ®Google Scholar
• Clark DE, Smith SK, Licence D, et al. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol. 1998;159(3):459–467.
   PubMed Web of Science ®Google Scholar
• Surmon L, Bobek G, Makris A, et al. Variability in mRNA expression of fms-like tyrosine kinase-1 variants in normal and preeclamptic placenta. BMC Res Notes. 2014;7:154.
   PubMedGoogle Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9–23.
   PubMed Web of Science ®Google Scholar
• Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Human Hypertens. 2017;31:782–786.
   PubMed Web of Science ®Google Scholar
• Mohammed KA, Nasreen N, Tepper RS, et al. Cyclic stretch induces PlGF expression in bronchial airway epithelial cells via nitric oxide release. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L559–L566.
   PubMed Web of Science ®Google Scholar
• Yao YG, Yang HS, Cao Z, et al. Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism. FEBS Lett. 2005;579(5):1227–1234.
   PubMed Web of Science ®Google Scholar
• De Ceuninck F, Dassencourt L, Anract P. The inflammatory side of human chondrocytes unveiled by antibody microarrays. Biochem Biophys Res Commun. 2004;323(3):960–969.
   PubMed Web of Science ®Google Scholar
• De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):1–9.
   PubMed Web of Science ®Google Scholar
• Helske S, Vuorela P, Carpén O, et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod. 2001;7(2):205–210.
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88(11):5555–5563.
   PubMed Web of Science ®Google Scholar
• Hod T, Cerdeira AS, Karumanchi SA. Molecular mechanisms of preeclampsia. Cold Spring Harb Perspect Med. 2015;5(10):a023473.
   PubMed Web of Science ®Google Scholar
• Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61(5):932–942.
   PubMed Web of Science ®Google Scholar
• Karumanchi SA. Angiogenic factors in pre-eclampsia: implications for clinical practice. Br J Obstet Gynaecol. 2018;125(11):1396.
   Google Scholar
• Dymara-Konopka W, Laskowska M, Blazewicz A. Angiogenic imbalance as a contributor of preeclampsia. Curr Pharm Biotechnol. 2018 Sep 25. Epub ahead of print. DOI:10.2174/1389201019666180925115559
   Google Scholar
• Ehrlich L, Hoeller A, Golic M, et al. Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia. Hypertens Pregnancy. 2017;36(2):175–185.
   PubMed Web of Science ®Google Scholar
• Hoeller A, Ehrlich L, Golic M, et al. Placental expression of sFlt-1 and PlGF in early preeclampsia vs early IUGR vs. Age-matched healthy pregnancies. Hypertens Pregnancy. 2017;36(2):151–160.
   PubMed Web of Science ®Google Scholar
• Holme AM, Roland MCP, Henriksen T, et al. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Am J Obstet Gynecol. 2016;215:782.e1-9.
   PubMed Web of Science ®Google Scholar
• Gonzales SK, Badell M, Cottrell H, et al. Villous explants from preeclamptic placentas induce sFlt1 in PBMCs: an ex vivo co-culture study. Pregnancy Hypertens. 2018 Apr;12:40–46. Epub 2018 Feb 25.
   PubMed Web of Science ®Google Scholar
• Benirschke K, Kaufmann P, Baergen RN. Pathology of the human placenta. 5th ed. New York, NY: Springer; 2006.
   Google Scholar
• Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40(6):463–471.
   PubMed Web of Science ®Google Scholar
• Saleh L, Van Den Meiracker AH, Geensen R, et al. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2018;51:751–757.
   PubMed Web of Science ®Google Scholar
• Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1:1356–1370.
   PubMed Web of Science ®Google Scholar
• Green CJ, Lichtlen P, Huynh NT, et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res. 2001;61:2696–2703.
   PubMed Web of Science ®Google Scholar
• Cianfarani F, Zambruno G, Brogelli L, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol. 2006;169:1167–1182.
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Kawamoto A, Tjwa M, et al. PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS ONE. 2011;6:e24872.
   PubMed Web of Science ®Google Scholar
• Rosenberger C, Solovan C, Rosenberger AD, et al. Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Invest Dermatol. 2007;127(10):2445–2452.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623–628.
   PubMed Web of Science ®Google Scholar
• Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336–3343.
   PubMed Web of Science ®Google Scholar
• Ishida A, Murray J, Saito Y, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol. 2001;188:359–368.
   PubMed Web of Science ®Google Scholar
• Andersson MK, Göransson M, Olofsson A, et al. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop. BMC Cancer. 2010;10:249.
   PubMed Web of Science ®Google Scholar
• Schimanski CC, Zimmermann T, Schmidtmann I, et al. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFR alpha in colorectal cancer. Int J Colorectal Dis. 2010;25(2):181–186.
   PubMed Web of Science ®Google Scholar
• Krüssel JS, Casañ EM, Raga F, et al. Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium. Mol Hum Reprod. 1999;5(5):452–458.
   PubMed Web of Science ®Google Scholar
• Shantha Kumara HMC, Cabot JC, Yan X, et al. Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection. Surg Endosc. 2011;25(7):2153–2158.
   PubMed Web of Science ®Google Scholar
• Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut. 2005;54(5):666–672.
   PubMed Web of Science ®Google Scholar
• Meng Q, Duan P, Li L, et al. Expression of placenta growth factor is associated with unfavorable prognosis of advanced-stage serous ovarian cancer. Tohoku J Exp Med. 2018;244(4):291–296.
   PubMed Web of Science ®Google Scholar
• Toi M, Bando H, Ogawa T, et al. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 2002;98(1):14–18.
   PubMed Web of Science ®Google Scholar
• Verrax J, Defresne F, Lair F, et al. Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy. Mol Pharm. 2011;8(3):701–708.
   PubMedGoogle Scholar
• Scheufler KM, Drevs J, van Velthoven V, et al. Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man. J Cereb Blood Flow Metab. 2003;23(1):99–110.
   PubMed Web of Science ®Google Scholar
• Alisi A, Da Sacco L, Bruscalupi G, et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest. 2011;91(2):283–293.
   PubMed Web of Science ®Google Scholar
• Medinger M, Halter J, Heim D, et al. Angiogenic markers in plasma cell myeloma patients treated with novel agents. Anticancer Res. 2015;35:1085–1090.
   PubMed Web of Science ®Google Scholar
• Chelli D, Hamdi A, Saoudi S, et al. Clinical assessment of soluble FMS-like tyrosine kinase-1/placental growth factor ratio for the diagnostic and the prognosis of preeclampsia in the second trimester. Clin Lab. 2016;62(10):1927–1932.
   PubMed Web of Science ®Google Scholar
• Litwińska E, Litwińska M, Oszukowski P, et al. Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markers. Adv Clin Exp Med. 2017;26(3):439–448.
   PubMed Web of Science ®Google Scholar
• Lesmes C, Gallo DM, Gonzalez R, et al. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks. Ultrasound Obstet Gynecol. 2015;46(3):341–349.
   PubMed Web of Science ®Google Scholar
• Poon LC, Lesmes C, Gallo DM, et al. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. Ultrasound Obstet Gynecol. 2015;46(4):437–445.
   PubMedGoogle Scholar
• Ukah UV, Hutcheon JA, Payne B, et al. Placental growth factor as a prognostic tool in women with hypertensive disorders of pregnancy: a systematic review. Hypertension. 2017;70(6):1228–1237.
   PubMed Web of Science ®Google Scholar
• Di Martino D, Cetin I, Frusca T, et al. Italian advisory board: sFlt-1/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management. Eur J Obstet Gynecol Reprod Biol. 2016;206:70–73.
   PubMed Web of Science ®Google Scholar
• Herraiz I, Llurba E, Verlohren S, et al. Spanish group for the study of angiogenic markers in preeclampsia update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/PlGF ratio in singleton pregnancies. Fetal Diagn Ther. 2018;43(2):81–89.
   PubMed Web of Science ®Google Scholar
• Moser G, Huppertz B. Implantation and extravillous trophoblast invasion: from rare archival specimens to modern biobanking. Placenta. 2017;56:19–26.
   PubMed Web of Science ®Google Scholar
• Moser G, Gauster M, Orendi K, et al. Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel confrontation co-culture models. Hum Reprod. 2010;25(5):1127–1136.
   PubMed Web of Science ®Google Scholar
• Moser G, Weiss G, Sundl M, et al. Extravillous trophoblasts invade more than uterine arteries: evidence for the invasion of uterine veins. Histochem Cell Biol. 2017;147(3):353–366.
   PubMed Web of Science ®Google Scholar
• He N, van Iperen L, de Jong D, et al. Human extravillous trophoblasts penetrate decidual veins and lymphatics before remodeling spiral arteries during early pregnancy. PLoS One. 2017;12(1):e0169849.
   PubMed Web of Science ®Google Scholar
• Windsperger K, Dekan S, Pils S, et al. Extravillous trophoblast invasion of venous as well as lymphatic vessels is altered in idiopathic, recurrent, spontaneous abortions. Hum Reprod. 2017;32(6):1208–1217.
   PubMed Web of Science ®Google Scholar
• Huppertz B. Biology of preeclampsia: combined actions of angiogenic factors, their receptors and placental proteins. Biochim Biophys Acta 2018. under review.
   Google Scholar
• Moser G, Drewlo S, Huppertz B, et al. Trophoblast retrieval and isolation from the cervix: origins of cervical trophoblasts and their potential value for risk assessment of ongoing pregnancies. Hum Reprod Update. 2018 Mar 28. [Epub ahead of print] PMID: 29608700. DOI:10.1093/humupd/dmy008
   PubMed Web of Science ®Google Scholar
• Imudia AN, Suzuki Y, Kilburn BA, et al. Retrieval of trophoblast cells from the cervical canal for prediction of abnormal pregnancy: a pilot study. Hum Reprod. 2009;24:2086–2092.
   PubMed Web of Science ®Google Scholar
• Amorim MG, Valieris R, Drummond RD, et al. A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. Sci Rep. 2017;7(1):14395.
   PubMedGoogle Scholar
• Yokoi A, Yoshioka Y, Hirakawa A, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811–89823.
   PubMedGoogle Scholar
• Satagopam V, Gu W, Eifes S, et al. Integration and visualization of translational medicine data for better understanding of human diseases. Big Data. 2016;4(2):97–108.
   PubMed Web of Science ®Google Scholar